SCHEMBL1689446

SCHEMBL1689446

NC(=O)C(Cc1ccc(C(=O)Nc2cc(-c3ccccc3)ccc2N)cc1)C(=O)N(c1ccccc1)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 19/20 0.61
HDAC3 O15379 5/20 0.61
HDAC2 Q92769 4/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1689267 0.90 HDAC1 (0.63) HDAC1HDAC2
SCHEMBL1689494 0.89 HDAC1 (0.64) HDAC1HDAC3HDAC2
SCHEMBL1689312 0.85 HDAC2 (0.62) HDAC1HDAC3HDAC2
SCHEMBL2108848 0.81 HDAC1 (0.76) HDAC1HDAC3HDAC2
SCHEMBL18653508 0.81 HDAC1 (0.76) HDAC1HDAC3HDAC2
SCHEMBL1689263 0.80 HDAC1 (0.77) HDAC1HDAC3HDAC2
SCHEMBL3771409 0.79 HDAC1 (0.76) HDAC1HDAC3HDAC2
SCHEMBL4580508 0.78 HDAC1 (0.77) HDAC1HDAC3HDAC2
SCHEMBL2107833 0.77 HDAC1 (0.64) HDAC1HDAC3HDAC2
SCHEMBL1689215 0.77 HDAC2 (0.75) HDAC1HDAC3HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1896395-B1 MODIFIED MALONATE DERIVATIVES MERCK SHARP & DOHME (US) 2015-07-15 EP claimed
EP-1896395-A2 MODIFIED MALONATE DERIVATIVES Merck & Co., Inc. (US) 2008-03-12 EP claimed
WO-2007002248-A2 MODIFIED MALONATE DERIVATIVES MERCK & CO., INC. (US) 2007-01-04 WO claimed
US-8158825-B2 Modified malonate derivatives MERCK SHARP & DOHME CORP. (US) 2012-04-17 US disclosed
US-20100160327-A1 Modified Malonate Derivatives MERCK SHARP & DOHME LLC 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160327-A1 Modified Malonate Derivatives ME2, ME3, ME1 HDAC1 6/4885HDAC3 17/4885HDAC2 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.